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Since Notch phenotypes in Drosophila melanogaster were first identified 100 years ago, Notch signaling has
been extensively characterized as a regulator of cell-fate decisions in a variety of organisms and tissues.
However, in the past 20 years, accumulating evidence has linked alterations in the Notch pathway to tumor-
igenesis. In this review, we discuss the protumorigenic and tumor-suppressive functions of Notch signaling,
and dissect the molecular mechanisms that underlie these functions in hematopoietic cancers and solid
tumors. Finally, we link these mechanisms and observations to possible therapeutic strategies targeting
the Notch pathway in human cancers.This year will be the centennial of the discovery of a signaling
pathway that has fascinated developmental, molecular, and
cancer biologists around the world. Mutant Notch phenotypes
in the fly wing were characterized by John S. Dexter 100 years
ago (Dexter, 1914), and, rapidly thereafter, Thomas HuntMorgan
identified the mutant alleles (Morgan, 1917). Almost seven de-
cades later, after the molecular biology revolution, Spyros
Artavanis-Tsakonas andMichael Young cloned theNotch recep-
tor and attributed the wing-notching phenotype to gene haploin-
sufficiency (Kidd et al., 1986;Wharton et al., 1985). These studies
brought about a revolution in a large number of fields, including
developmental and stem cell biology, neuroscience, and (related
to this review) cancer biology (Fortini et al., 1993). Indeed, in the
early 1990s, gain-of-function mutations of the pathway were
identified in cancer (Ellisen et al., 1991; Gallahan and Callahan,
1997; Gallahan et al., 1987; Jhappan et al., 1992). A deluge of
reports followed, cementing the role of Notch signaling as onco-
genic but also tumor suppressive, depending on the context. In
this review, we attempt to provide a detailed characterization of
Notch functions in both solid and hematopoietic cancers. In
addition, we discuss the molecular mechanisms that underlie
such functions, as well as approaches to target Notch signaling
in human cancers.
A Brief Description of the Notch Signaling Pathway
There are four Notch receptors (named Notch1–Notch4) in
mammals. Notch1 and Notch2 each have 36 epidermal growth
factor (EGF)-like repeats, while Notch3 and Notch4 have 34
and 29 repeats, respectively, which affects their affinity for cor-
responding ligands (Haines and Irvine, 2003; Okajima and Irvine,
2002; Rebay et al., 1991; Figure 1). Notch receptors are single-
pass type I transmembrane molecules coded by a single pre-
cursor that becomes a noncovalently linked heterodimer. This
heterodimer consists of an N-terminal extracellular (NEC) frag-
ment and a C-terminal transmembrane-intracellular subunit
(NTM) as a result of cleavage by a furin-like protease in the
trans-Golgi network (Blaumueller et al., 1997; Figures 1 and 2).
The Notch pathway is normally activated upon interactions318 Cancer Cell 25, March 17, 2014 ª2014 Elsevier Inc.with ligands such as Delta-like and Jagged, which are also trans-
membrane proteins containing EGF-like repeats. In mammals,
there are three Delta-like ligands (Dll1, Dll3, and Dll4) and two
Jagged ligands (Jag1 and Jag2). The Notch pathway is activated
in a strictly controlled fashion: ADAM10/17 metalloproteases
cause an S2 cleavage in the receptor, followed by a third cleav-
age (S3 cleavage) mediated by the presenilin-g-secretase
complex, which is composed of presenilin 1 (PSEN1), PSEN2,
nicastrin (NCSTN), presenilin enhancer 2 (PEN2), and anterior
pharynx-defective 1 (APH1) (Shah et al., 2005). This series of
events releases the intracellular portion of the Notch receptor
(termed ICN), which then translocates into the nucleus to
mediate target gene activation (De Strooper et al., 1999; Schro-
eter et al., 1998). Notch-ICN is a transcriptional activator (Bray,
2006) consisting of ankyrin repeats, a RAM (RBP-Jk associated
molecule) domain, a transactivation domain (TAD), a nuclear
localization signal (NLS), and a PEST domain that regulates
protein stability (Figures 1 and 2). Notch ligands are also cleaved
by g-secretase and ADAM metalloprotease complexes, thus
providing an additional level of regulation of the pathway (LaVoie
and Selkoe, 2003; Six et al., 2003). Despite the overall similarities
between the receptors, the differences in the ligand-binding
extracellular domains and the transactivation intracellular do-
mains lead to distinct ligand affinities and capacities to activate
downstream transcription.
In the nucleus, Notch binds to initially inactive CBF1-Su(H)-
LAG1 (CSL) (aka RBP-Jk)-containing complexes and mediates
their conversion to a transcriptional activator followed by
the recruitment of the coactivator protein mastermind-like 1
(MAML1) (Figure 2; Nam et al., 2006; Wilson and Kovall, 2006;
Wu et al., 2000). The ankyrin repeats seem to play an important
role in MAML1 recruitment. The list of target genes regulated by
Notch is very much dependent on cell type and can include
genes whose products are involved in fundamental aspects of
cell biology, such as cell-cycle regulation (Joshi et al., 2009;
Lewis et al., 2007), cellular differentiation, and metabolism (Pal-
omero et al., 2006). Common targets of the pathway include
the HES and HEY families of transcription repressors (Iso et al.,
Figure 1. Protein Structure and Mutations of a Typical Notch Receptor
The structure of the NOTCH1 receptor and genetic alterations of the protein in representative types of cancer are depicted. ADAM metalloproteases and the g-
secretase complex cleave the receptor and free the ICN domain. Major mutations are clustered according to their effects on protein activity. Both gain- and loss-
of-function mutations are shown. The majority of the T-ALL mutations are clustered in the heterodimerization (HD) and PEST domains that control processing of
the receptors by proteases and the stability of the protein, respectively. Different characteristic cases of hematopoietic disorders (affecting NOTCH2 as well) are
shown. In CLL tumors, there is an apparent mutational hotspot at the PEST domain of NOTCH1. In the case of SqCCmutations, mutations are mainly clustered in
the EGF repeat region, potentially affecting interaction with the ligands. T-ALL, T cell acute lymphoblastic leukemia; SMZL, splenic marginal zone lymphoma;
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; SqCC, squamous cell carcinoma. Percentages are approximations based on current
literature.
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scription factor (Palomero et al., 2006; Sharma et al., 2006;
Weng et al., 2006). The binding of Notch on DNA appears to
be a rapid and dynamic process controlled by the kinase
CDK8 and the ubiquitin ligase Fbxw7, followed by phosphoryla-
tion, ubiquitination, and proteasomal degradation of Notch
(Fryer et al., 2004; Mukherjee et al., 2005; O’Neil et al., 2007;
Thompson et al., 2007), which shuts off the pathway (Figure 2).
Various tools have been developed to study the transcriptional
activity of the pathway, such as chromatin immunoprecipitation
sequencing (ChIP-seq) and ChIP-chip to map Notch1 binding on
the genome (Castel et al., 2013; Ntziachristos et al., 2012;
Palomero et al., 2006; Wang et al., 2011a), and mouse models
that allow efficient tracing of receptor cleavage/activity in many
different tissues (Hansson et al., 2006; Liu et al., 2011; Mizutani
et al., 2007; Souilhol et al., 2006). Recently, the group of Artava-
nis-Tsakonas (Fre et al., 2011; Sale et al., 2013) and members of
our laboratory (Oh et al., 2013) traced Notch pathway activity
in vivo by using reporter systems for Notch receptor expression
and Hes1 activity by coupling them to fluorescent proteins
(Figure 3). Since there are several unanswered questions
regarding Notch ligand expression, even under physiological
conditions, an exciting next step could involve the development
of fluorescent tools to probe ligand expression together with
pathway activation in real time within a living organism.
NOTCH Signaling Pathway in Cancer
The Notch pathway is genetically altered in a large number of
hematopoietic and solid tumors (Figure 1). Intriguingly, these
alterations can lead to either activation or repression of the
pathway depending on the context and the activation status of
other potentially oncogenic pathways (Table 1; Figure 4). Inter-
estingly, it appears that there are multiple and distinct modes
of aberrant regulation of the pathway and its targets in cancer.They include activating and inactivating mutations, receptor/
ligand overexpression, epigenetic regulation, and effects of
posttranslational modifications, most notably receptor and
ligand fucosylation (especially O-fucosylation) (Haines and
Irvine, 2003; Lei et al., 2003; Okajima et al., 2003) and ubiquitina-
tion (Fryer et al., 2004; Thompson et al., 2007). We initially
discuss T cell acute lymphoblastic leukemia (T-ALL), a disease
in which Notch has a well-characterized oncogenic role. Subse-
quently, we present several other cases of hematopoietic and
solid tumors in which Notch has tumor-suppressive or onco-
genic roles, along with its potential mechanisms of action and
partners.
T-ALL
NOTCH1 is a master transcription factor that controls innate and
adaptive immunity, and plays an important role in directing
hematopoietic development toward T cells (Aifantis et al.,
2008; Li and von Boehmer, 2011; Radtke et al., 2013). The very
first finding of Notch pathway alterations in cancer was made
by Ellisen et al. (1991), who revealed a rearrangement between
the intracellular part of NOTCH1 (ICN1) and the T cell receptor
beta (TRB) locus that leads to high-level expression of truncated,
constitutively active NOTCH1 in leukemia. Subsequent in vitro
studies (Capobianco et al., 1997) and animal modeling (Girard
et al., 1996; Pear et al., 1996) by other groups further confirmed
this finding and proved that ICN1 is a strong oncogenic allele.
Most importantly, 10 years ago, the Aster and Look laboratories
reported the first activating NOTCH1 mutations in human T-ALL,
occurring in approximately 50% of all cases (Weng et al., 2004).
The majority of these mutations encompass single amino acid
substitutions, insertions, and deletions located in exons 26 and
27 of the genetic locus, which encode the N-terminal and
C-terminal components, respectively, of the heterodimerization
domain. Thesemutations lead to lower protection of S2 cleavage
of Notch, resulting in either ligand-independent activation orCancer Cell 25, March 17, 2014 ª2014 Elsevier Inc. 319
Figure 2. Overview of the Notch Signaling Pathway
A visual description of the signaling cascade is shown for the signal-receiving
cell (i.e., the cell expressing the Notch receptor). The pathway inhibitors used
include antibodies against NOTCH receptors and DLL ligands, GSIs, and small
peptides that inhibit formation of the transcriptional complex. Antibody-based
treatments are shown in purple, GSI compounds are in pink, and peptide-
based drugs are in red. Potential epigenetic inhibitors (in green) can include
BRD inhibitors such as JQ1. HDAC, histone deacetylase; ICN1, intracellular
part of NOTCH1; LSD1, lysine-specific demethylase 1; SMRT, Silencing-
Mediator for Retinoid/Thyroid hormone receptors; GSK3b, glycogen synthase
kinase 3 beta; DNMAML1, dominant-negative MAML1.
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of mutations, known as juxtamembrane expansion (JME)
mutants, also augments NOTCH1 activation at the cell
membrane (Sulis et al., 2008; Figure 1). Finally, PEST domain
mutants encompass another category of NOTCH1 mutations
in 20%–25% of T-ALLs. PEST domain alterations lead to trun-
cation or loss of the domain due to frameshift or nonsense nucle-
otide substitutions, which impair proteasomal degradation
mediated by the ubiquitin ligase FBXW7 and lead to higher
ICN1 cellular concentrations (Weng et al., 2004). The importance
of ICN1 degradation in physiology is further evidenced by the
fact that 15% of T-ALL cases harbor mutations or deletions in
FBXW7 (Asnafi et al., 2009; O’Neil et al., 2007; Thompson
et al., 2007). These changes are localized in three arginine resi-
dues that are critical for its interaction with ICN1. Mutations in320 Cancer Cell 25, March 17, 2014 ª2014 Elsevier Inc.the PEST domain and FBXW7 do not occur concurrently, which
implies that they play the same role to increase the stability of
ICN1 (Asnafi et al., 2009; O’Neil et al., 2007).
The fact that FBXW7 mutations directly affect cells with
leukemia-initiating properties though the stabilization and over-
expression of MYC, another well-characterized substrate of
this ubiquitin ligase, further demonstrates that NOTCH and
MYC actions are intertwined in cancer cells (King et al., 2013).
Interestingly, NOTCH1 mutations in T-ALL were shown to have
a favorable prognosis and better outcome after treatment in a
number of studies, including the ALL-Berlin-Frankfurt-Munster
2000 study (Breit et al., 2006), the Japan Association of Child-
hood Leukemia Study that examined NOTCH1 and FBXW7
mutational status in T-ALL and T cell lymphoblastic lymphoma
patients (Park et al., 2009), and the Lymphoblastic Acute Leuke-
mia in Adults (LALA)-94 and GRAALL-2003 trials (Asnafi et al.,
2009). Finally, another report on 134 pediatric patients from the
EORTC-CLG 58881 and 58951 protocols concluded that
NOTCH1 and FBXW7 mutations are associated with improved
early chemotherapeutic response and lower minimal residual
disease levels (Clappier et al., 2010). It remains to be seen
whether Notch pathway inhibition can be used successfully to
target T-ALL, especially in relapsed disease that is refractory
to conventional chemotherapy-based treatments.
Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common leuke-
mia in adults. Recently, it was demonstrated using next-genera-
tion sequencing-based approaches that 10%–12% of CLL
cases exhibit activating mutations of NOTCH1, underlining the
significance of such mutations as a prognostic marker. The
vast majority of these mutations are in the PEST domain, leading
to truncated protein variants with a longer half-life (Figure 1).
Interestingly, there seems to be a mutational hotspot in this
disease, with P2515Rfs being the most prevalent mutation (Fab-
bri et al., 2011; Puente et al., 2011; Rossi et al., 2012a).Mutations
of NOTCH1 are mutually exclusive with TP53 abnormalities, and
survival outcomes are poor in both cases (Rossi et al., 2012a;
Wickremasinghe et al., 2011). NOTCH1 and SF3B1 (a splicing
factor) mutations were associated with decreased overall
survival, and both retained independent prognostic significance
for survival outcomes (Oscier et al., 2013). In a study by Fabbri
et al. (2011), mutational activation of NOTCH1 was found to
occur with significantly higher frequency during disease progres-
sion toward the high-risk Richter transformation (30%) and
chemorefractory CLL (20%). That study and a very recent
large-scale clinical analysis of CLL patients (Weissmann et al.,
2013) confirmed that NOTCH1 mutations are an adverse prog-
nostic parameter in this disease.
Lymphoma
Non-Hodgkin lymphoma (NHL) is a heterotypic mix of
diseases, the most prevalent being Burkitt lymphoma, follicular
lymphoma (FL, the most indolent of NHL cases) (Pasqualucci
et al., 2014; Roulland et al., 2011), and diffuse large B cell
lymphoma (DLBCL). In one study, Burkitt lymphomas, which
are mainly characterized by the upregulation of MYC due to
its translocation to the immunoglobulin locus, displayed recur-
rent gain-of-function NOTCH1 mutations in 8%–9% of patients
(Love et al., 2012). FL and DLBCL are malignancies of B cell
origin and together account for 60% of new NHL diagnoses in
Figure 3. In Vivo Mapping of Notch Pathway Activity Using a Hes1GFP Reporter
(A) Targeting strategy for the generation of transgenic animals expressing Emerald GFP (emGFP) from the endogenous Hes1 locus.
(B) Immunofluorescence staining for the thymus of Hes1GFPmice. DAPI stains DNA (nucleus), VE-cadherin is a vascular endothelial marker, and K14 is amarker of
thymic medullary cells.
(C) Increased levels of Notch pathway help differentiation of thymic T cell progenitors through the DN2/3 CD48 differentiation stage, and the pathway activity is
decreased immediately at the DP stage.
(D) Activity of the Notch pathway in the mouse bone marrow is detected at the HSC level and is decreased as cells differentiate. Subsequently, it is reactivated at
the level of a megakaryocytic-erythrocytic progenitor (MEP). HSC, hematopoietic stem cell; MPP, multipotent progenitor; CMP, common myeloid progenitor;
CLP, common lymphoid progenitor; MEP, megakaryocyte-erythrocyte progenitor; GMP, granulocyte-macrophage progenitor; DN, double negative
(CD4CD8); DP, double positive (CD4+CD8+); SP, single positive.
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subtype are derived from GCB cells, whereas the more aggres-
sive activated B cell (ABC) DLBCL subtype is most likely
derived from cells that have exited the germinal center.
NOTCH2 is mutated in 8% of DLBCL cases (Lee et al.,
2009). These are mainly gain-of-function mutations that affect
the PEST domain (and thus the stability of the protein), as well
as copy number alterations (Morin et al., 2011). Interestingly,
NOTCH2 is required for B cell development in the splenic
marginal zone (SMZ) environment and has been implicated in
SMZ lymphoma (SMZL) (Kiel et al., 2012; Rossi et al., 2012b),
as 20% of SMZL cases exhibit gain-of-function NOTCH2 muta-
tions accompanied by mutations of NOTCH1, SPEN, and DTX1
(Rossi et al., 2012b). It was suggested that these genetic
changes are associated with adverse prognosis (Kiel et al.,
2012). Finally, Jundt and colleagues have characterized an
activating role for NOTCH1 in classic Hodgkin lymphoma
(Schwarzer et al., 2012; Schwarzer and Jundt, 2011). These
authors suggested that NOTCH1 is activated through the upre-
gulation of its ligands within the tumor niche and suppresses
genes that are important for B cell identity, such as E12/E47
and early B cell factor (EBF) (Jundt et al., 2008). Additional
studies are required to better define Notch receptor and ligandexpression, and targeted signaling pathways in the distinct sub-
types of lymphoma.
Acute Myeloid Leukemia and Myelomonocytic
Neoplasms
Several years ago, emerging evidence indicated that the Notch
pathway could have tumor-suppressive roles in various types
of tumors, in stark contrast to its oncogenic role in the aforemen-
tioned hematopoietic malignancies (Nicolas et al., 2003; Rangar-
ajan et al., 2001). In contrast to the tumorigenic role of NOTCH1
in T-ALL, our laboratory and others recently characterized a
tumor-suppressive role of the Notch pathway in myeloid malig-
nancies. We showed that deletion of nicastrin (Ncstn), an essen-
tial component of the g-secretase complex, leads to the induc-
tion of chronic myelomonocytic leukemia (CMML) (Klinakis
et al., 2011), a disease characterized by increased extra-
medullary hematopoiesis, monocytosis, myeloproliferation, and
frequent progression to acute myeloid leukemia (AML). This is
a Notch-mediated effect, as compound deletion of Notch1/2
in vivo led to similar effects. In support of this, an analysis of
the conditional model for the deletion of FX (the homolog of
human GDP-L-fucose synthase) or O-fucosyltransferase 1
(Pofut1) showed myeloid hyperplasia (Yao et al., 2011), underlin-
ing the importance of Notch receptor fucosylation for ligandCancer Cell 25, March 17, 2014 ª2014 Elsevier Inc. 321
Table 1. Oncogenic and Tumor-Suppressive Roles of Notch Signaling in Human Cancers
Tumor Type
Oncogene or
Tumor Suppressor
Mutations (%) and Noteworthy
Observations References
T cell acute lymphoblastic
leukemia (T-ALL)
oncogene 50%–60% NOTCH1, 30% FBXW7 Malyukova et al., 2007;
Weng et al., 2004role in cancer initiation and maintenance
Chronic lymphocytic
leukemia (CLL)
oncogene 5%–12% NOTCH1 Fabbri et al., 2011;
Puente et al., 2011role in cancer initiation and survival
Melanoma oncogenic 50% NOTCH1 overexpression in human samples Balint et al., 2005;
Bedogni et al., 2008possible role in metastasis
Cholangiocarcinoma
(CCC)
oncogenic 35% FBXW7 Akhoondi et al., 2007;
Zender et al., 2013Notch1 promotes tumor initiation and maintenance
Colorectal cancer oncogenic 8%–9% FBXW7 Miyaki et al., 2009 ;
Akhoondi et al., 2007crosstalk with Wnt and Hippo signaling
Lung adenocarcinoma oncogenic 10% NOTCH1 Licciulli et al., 2013;
Westhoff et al., 2009;
Zheng et al., 2013
role in initiation and maintenance (Notch1),
and metastasis (Jagged2)
specific role for Notch3 in tumor propagation
Glioblastoma oncogenic role in tumor propagation and radioresistance Chu et al., 2013; Wang et al., 2010
Renal cell carcinoma oncogenic role in progression and maintenance Sjo¨lund et al., 2008
Ovarian cancer oncogenic role in maintenance and therapy response Cancer Genome Atlas
Research Network, 2011;
McAuliffe et al., 2012
Prostate oncogenic activation of the pathway associated with tumor
progression, metastasis, and recurrence
Marignol et al., 2013;
Santagata et al., 2004
Breast cancer mostly oncogenic NOTCH1 and NOTCH4 fusions Fu et al., 2010;
Imatani and Callahan, 2000;
Jhappan et al., 1992
potential NOTCH2 dominant-negative truncated
mutant
other alterations activate Notch signaling, but
hyperactive Notch signaling may inhibit cancer
growth
Pancreatic ductal
adenocarcinoma (PDAC)
mostly oncogenic Notch2 loss inhibits progression and maintenance Hanlon et al., 2010;
Mazur et al., 2010;
Mullendore et al., 2009
overexpression of ligands (Jagged2 [90%], Dll4
[50%], but Notch1 loss may promote tumor
initiation
Cervical cancer mostly oncogenic pathway activation in human tumors, but dose-
dependent effects
Bajaj et al., 2011;
Maliekal et al., 2008;
Zagouras et al., 1995possible role in tumor-propagating cells
Head and neck squamous
cell carcinomas (HNSCC)
mostly oncogenic possible bimodal pattern of Notch pathway
alterations with a small subset of tumors with
inactivating NOTCH1 mutations, but a larger
group with pathway activation
Sun et al., 2014
Hepatocellular carcinoma
(HCC)
oncogenic and tumor
suppressive
context-dependent effects that may be related
to various molecular subtypes
Qi et al., 2003;
Villanueva et al., 2012
Medulloblastoma oncogenic and tumor
suppressive
opposite roles for Notch1 and Notch2 Fan et al., 2004
B cell acute lymphoblastic
leukemia (B-ALL)
tumor suppressive no mutations Zweidler-McKay et al., 2005
role in maintenance (activation induces growth
arrest and death)
Acute myeloid leukemia
(AML)
tumor suppressive Notch1 and Notch2 are expressed, but the
pathway is not active
Kannan et al., 2013;
Lobry et al., 2013
role in cancer initiation and maintenance
Small cell lung carcinoma
(SCLC)
tumor suppressive no mutations Sriuranpong et al., 2001
inhibits tumor maintenance (possible similar role
in other neuroendocrine tumor types)
(Continued on next page)
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Table 1. Continued
Tumor Type
Oncogene or
Tumor Suppressor
Mutations (%) and Noteworthy
Observations References
Lung squamous cell
carcinoma (SqCC)
tumor suppressor 5%–12.5% NOTCH1 and NOTCH2 Cancer Genome Atlas Research
Network, 2012; Wang et al., 2011b
Cutaneous squamous
cell carcinoma (SqCC)
tumor suppressor 60%–75% NOTCH1 and NOTCH2 Wang et al., 2011b
Chronic myelomonocytic
leukemia (CMML)
tumor suppressor 12% various pathway genes (NCSTN,
APH1, MAML1, and NOTCH2)
Klinakis et al., 2011
role in cancer initiation
The cancers indicated in this table have been selected for historical reasons (first examples of mutations in the Notch pathway), because they affect
large populations of cancer patients, or because of the particular insight of some studies into the role of Notch signaling in cancer. Selected obser-
vations and references are shown for the selected tumor types; see text for additional references and details. In particular, data from large cancer
genome efforts indicate that many alterations in the extended Notch pathway exist in human tumors; most of these alterations are awaiting additional
analyses and functional validation.
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similar phenotypes (Chen et al., 2008). Mechanistically, the
tumor-suppressor role of NOTCH in this disease is mediated
by direct repression of the PU.1 and CEBPa promoters by
HES1. Subsequent screening of primary CMML samples for
Notch pathway mutations showed that NCSTN, MAML1,
APH1A, and NOTCH2 are mutated and genetically inactivated
in about 12% of CMML patients. These mutations are unique
to CMML and are not found in other myeloproliferative disorders,
such as polycythemia vera andmyelofibrosis. Notch-inactivating
mutations co-occurred with other described myeloid mutations
in genes such as TET2, FLT3, and ASXL1 (Klinakis et al., 2011).
Based on these findings, we were able to show that the combi-
nation of Notch pathway and TET2 inactivation leads to AML.
AML cells specifically express NOTCH2 on their surface, but
show no signs of pathway activity. Interestingly, reactivation of
the Notch pathway in established AML leads to complete dis-
ease remission (Kannan et al., 2013; Lobry et al., 2013). This
observation provides a rationale for the use of specific
NOTCH2-activating antibodies or specific agonists as a viable
therapeutic strategy in this type of leukemia. Mechanistically,
there might be several ways to suppress Notch pathway activity
in AML. Initially, AML cells might reside in microenvironments
that lack Notch ligands. Another putative mechanism is epige-
netic silencing achieved by DNA and histone methylation of
target gene promoters/transcriptional start sites. In agreement
with this possibility, we found that Notch target genes are char-
acterized by H3K27me3 marks (Lobry et al., 2013), and mice
carrying the R132H mutation of isocitrate dehydrogenase 1
(IDH1) (Figueroa et al., 2010; Gross et al., 2010; Xu et al., 2011)
develop a myeloproliferative disease characterized by marked
DNA hypermethylation of Notch pathway genes such as Lfng,
Maml3, and Hes5 (Sasaki et al., 2012).
B Cell ALL
Interestingly, Notch signaling also appears to act as a tumor
suppressor in B cell ALL (B-ALL). In agreementwith theAML find-
ings, a study by Zweidler-McKay et al. (2005) showed that Notch
pathway reactivation leads to growth inhibition and induces
apoptosis in human B-ALL cells. In a recent follow-up publica-
tion, it was shown that several Notch pathway targets in B-ALL
are suppressed by DNA cytosine hypermethylation on their
promoters, followed by histone H3K27 and H3K9 trimethylation(Kuang et al., 2013). The parallel between AML and B-ALL is
intriguing and potentially can be explained by a recent Notch ac-
tivitymapping effort (Oh et al., 2013) that demonstrated activity of
the pathway in T cell progenitors andpre-erythrocytes, and a lack
of pathway activation in the B cell andmyelomonocytic lineages.
These findings provide support for the notion that NOTCHplays a
key role as a developmental regulator in determining the fate of
progenitors in the hematopoietic system. In this model, NOTCH
action needs the addition of other oncogenic stimuli to transform
cells. In agreement with this idea, we found that Notch pathway
inactivation can lead to an increased frequency of granulocyte-
monocyte progenitors (GMPs), which can initiate diseases such
as CMML and AML upon further alterations (Klinakis et al., 2011).
Notch Signaling in Solid Tumors
A number of recent reviews have thoroughly summarized the
current knowledge about Notch signaling in solid tumors (Nowell
and Radtke, 2013; Ranganathan et al., 2011; South et al., 2012;
see also Table 1). Recent studies, including resources from The
Cancer Genome Atlas (TCGA), have provided genomic data that
underscore the prevalence and complexity of Notch pathway
alterations in human cancers; however, they have not provided
detailed functional interpretations of these alterations. Our goal
in the section below is not to provide an exhaustive list of the
solid tumor types in which Notch signaling is altered and the
possible consequences of these alterations. Rather, we aim to
highlight some key observations regarding a few prominent tu-
mor types and draw some points of discussion from relevant
studies, including the large number of partners used by Notch
(Figure 4) and the distinct roles of the four Notch receptors.
Breast Cancer
Breast cancer is a very prevalent form of cancer in which the
Notch pathway may act as a tumor suppressor or an oncogene
depending on the subtype. One of the first indications that Notch
signaling may play a role in solid tumors came from experiments
with mouse mammary tumor viruses (MMTVs). Integration of the
MMTV genome next to the ‘‘Int-3’’ locus resulted in an activating
mutation of Notch4, leading to the constitutive activation of the
receptor and breast cancer development (Gallahan and Calla-
han, 1997; Jhappan et al., 1992; Robbins et al., 1992). Since
this seminal discovery, a number of studies have confirmed
that activation of Notch signaling plays an oncogenic role inCancer Cell 25, March 17, 2014 ª2014 Elsevier Inc. 323
Figure 4. Simplified Scheme of Notch
Interactions with Other Signaling Pathways
in Cancer
The TGFb, PI3K, NFkB, and WNT pathways are
some of the most important pathways that interact
with NOTCH. Notably, Jagged 1 is activated by
the TGFb pathway and in turn activates NOTCH
receptors in neighboring cells. Phosphorylation of
NOTCH from the WNT-induced GSK3b leads to
ubiquitination through FBXW7 and final degrada-
tion. Also, a classical NOTCH target, HES1, re-
presses PTEN, a competitor of another pathway
with oncogenic roles, PI3K, which in turn activates
NFkB, a pathway that is important for leukemia
progression. Important parameters of the in-
teractions, such as regulation of NFkB pathway by
NOTCH through HES1 action, or interaction of
NOTCH with the WNT member DVL (Dishevelled)
protein, which inhibits both WNT and NOTCH
pathways, are not shown in this figure. ICJ1,
intracellular part of JAG1; ECJ1, extracellular part
of JAG1.
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et al., 2011; Xu et al., 2012). In breast cancer cells, Notch
signaling can be activated by functional interactions with other
signaling pathways, including the Ras and Wnt pathways
(Ayyanan et al., 2006; Fitzgerald et al., 2000; Izrailit et al., 2013;
Meurette et al., 2009; Weijzen et al., 2002). Recent observations
indicate that Notch4 may play a more specific role than other
Notch receptors in breast cancer stem cells (Harrison et al.,
2010). In contrast, a recent study indicated that hyperactivation
of NOTCH3may actually be detrimental to breast cancer cells by
inducing senescence (Cui et al., 2013). Interestingly, mammary
epithelial cells respond differently to different levels of activation
of the Notch pathway (Mazzone et al., 2010). Thus, although
accumulating evidence indicates that Notch is protumorigenic
in breast cancer, in certain contexts, specific (high) levels of
activation may be tumor suppressive. Alternatively, different
Notch receptors may have unique signaling outputs in mammary
epithelial cells or in different subtypes of breast cancer. Once
more, the notion of a ‘‘differentiation switch’’ could explain the
many faces of Notch signaling in this type of tumor.
Lung Cancer
Lung adenocarcinoma (LAC) is a major subtype of lung cancer.
Initial observations suggested that Notch signaling promotes
the expansion of LAC cells in culture (Dang et al., 2003; Eliasz
et al., 2010; Haruki et al., 2005). More recent in vivo studies
demonstrated that Notch signaling is a key promoter of LAC
development and maintenance (Allen et al., 2011; Licciulli
et al., 2013; Maraver et al., 2012), and that NOTCH3 plays a
unique role in the self-renewal of LAC tumor-propagating cells
(Zheng et al., 2013). Expression of JAG2 at the surface of lung
adenocarcinoma cells leads to homotypic interactions with
Notch receptors and promotes the metastatic potential of these
LAC stem cells (Yang et al., 2011). Thus, although mutations and
other alterations may not be frequent in LAC (Westhoff et al.,
2009), Notch pathway activity correlates significantly with worse
survival in lung cancer patients (Hassan et al., 2013; Zheng et al.,
2013), and activation of Notch may be important for the sus-
tained growth of LAC. Targeting NOTCH3 and/or JAG2 may
benefit a very large number of lung cancer patients worldwide.
Squamous cell lung carcinoma (SqCC) is the second major
type of non-small cell lung cancer. In stark contrast to LAC,324 Cancer Cell 25, March 17, 2014 ª2014 Elsevier Inc.Notch signaling is thought to be a tumor suppressor of SqCC
development, as evidenced by the identification of loss-of-func-
tion mutations in human tumors (Wang et al., 2011b). These
mutations mainly cluster in the EGF-like repeat region of
NOTCH1 and thus have the potential to disrupt ligand binding
or to produce truncated receptors (Figure 1). Although functional
validation of these observations is still missing owing to the
current lack of appropriate mouse models, numerous obser-
vations indicate that inactivation of Notch signaling promotes
the development of squamous cell carcinoma in other tissues,
including cutaneous and head-and-neck tumors (Agrawal
et al., 2012; Pickering et al., 2013; Proweller et al., 2006; Rothen-
berg and Ellisen, 2012; Wang et al., 2011b). These observations
suggest that loss of Notch pathway activity may be critical for
the growth of tumor cells with squamous differentiation charac-
teristics.
Small cell lung carcinoma (SCLC) is a neuroendocrine sub-
type of lung cancer. Although it accounts for a smaller fraction
of lung cancer cases (12%–15%), it has the highest mortality
rate. Genomic studies have failed to identify recurrent muta-
tions in the Notch pathway in SCLC (Peifer et al., 2012; Rudin
et al., 2012). However, early observations indicated that hyper-
activation of Notch signaling blocks the cell cycle of SCLC
cells (Sriuranpong et al., 2001, 2002). A tumor-suppressive
role for Notch in SCLC is supported by evidence that Notch
may play a similar role in other neuroendocrine tumors, such
as medullary thyroid carcinoma (Cook et al., 2010). Thus far,
however, no functional evidence has been obtained in vivo
that activation of Notch may block SCLC development or
maintenance, and it is still possible that subpopulations of
cells in SCLC tumors may display some Notch activity and
contribute to SCLC growth (Kluk et al., 2013; Salcido et al.,
2010).
Thus, three different subtypes of lung cancer display strik-
ingly different roles for Notch signaling in cancer development:
(1) actively oncogenic with rare genetic alterations in LAC, (2)
tumor suppressive with inactivating mutations in SqCC, and
(3) possibly tumor suppressive with no sign of mutations in
SCLC. It is possible that these differences are related to the
role of Notch in cell-fate decisions during lung embryonic
development.
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Genome sequencing analyses did not reveal recurrent mutations
in Notch pathway genes in hepatocellular carcinoma (HCC), a
leading cause of cancer-related deaths worldwide (Fujimoto
et al., 2012; Guichard et al., 2012). Nevertheless, Notch signaling
has been of interest to liver cancer biologists because of the
prominent role of Notch signaling in liver development, including
mutations inNOTCH2 or JAG1 in patients with Alagille syndrome
(syndromic bile duct paucity) (McDaniell et al., 2006; Oda et al.,
1997). Haploinsufficient mutations in a specific ligand and a
specific receptor in the Notch pathwaywould suggest that Notch
signaling could play very context- and level-dependent roles in
liver tumors. Initial observations suggested that low levels of
Notch correlate with high activity of the Wnt pathway, a major
oncogenic pathway in HCC (Wang et al., 2009). Also, high levels
of active Notch1may inhibit the expansion of HCC cells (Qi et al.,
2003), and deletion ofNotch1 in the liver of mice results in hyper-
proliferative hepatocytes, suggesting a tumor-suppressive role
for Notch in HCC (Croquelois et al., 2005). Similarly, Notch
signaling has a tumor-suppressive effect in HCC initiated by
inactivation of the RB pathway (Viatour et al., 2011). However,
more recent reports have provided evidence that Notch
signaling is active and oncogenic in HCC (Dill et al., 2013; Tscha-
harganeh et al., 2013; Villanueva et al., 2012), andmay be impor-
tant for the development of tumors following hepatitis B virus
infection (Jeliazkova et al., 2013). These observations suggest
that the role of Notch signaling in HCC may differ among the
distinct molecular subgroups of this cancer type, and under-
score the need to further explore the molecular contexts asso-
ciated with the tumor-suppressive or oncogenic roles of Notch
in the liver.
In contrast to the complex roles of Notch signaling in HCC,
accumulating evidence supports a protumorigenic role for
Notch signaling in cholangiocarcinoma (CCC). Mutations of
the Notch repressor FBXW7 are found in a subset of human
tumors (Akhoondi et al., 2007). Similar to the disruption of
bile ducts in Alagille patients, activation of Notch2 in liver pro-
genitors and adult hepatocytes promotes biliary tubulogenesis
(Jeliazkova et al., 2013). Finally, constitutive activation of
NOTCH1 is sufficient to initiate CCC development in mice (Zen-
der et al., 2013).
It is likely that the sometimes contradictory consequences of
Notch activation in liver cells are due to a combination of the
strength of the downstream signal, the timing of the activation,
the cell type in which this activation occurs, and the receptor
involved (Ortica et al., 2014). There seems to be a consensus
that higher Notch levels in liver progenitors favor bile duct differ-
entiation over hepatocytic differentiation. Possibly, activation of
Notch (e.g., NOTCH2) in these progenitors promotes CCC while
suppressing HCC (Guest et al., 2014). It is also possible that
Notch switches from a suppressive role in the early stages of
HCC development to a more oncogenic role. Although it was
proposed that Notch signaling plays a role in liver cancer inva-
sion and metastasis (Lim et al., 2011; Zhou et al., 2013), more
work is required to further support this notion.
Colorectal Cancer
The intestinal epithelium exhibits an unprecedented self-renewal
rate that appears to be linked to a high susceptibility tomalignant
transformation. Notch signaling has been known for many yearsnow to be involved in both the control of homeostatic self-
renewal in stem cell populations and the development of colo-
rectal cancer (CRC) (Fre et al., 2005; Radtke and Clevers,
2005; van Es et al., 2005). Although mutations in NOTCH genes
are rare, Notch signaling is overexpressed or constitutively acti-
vated in CRC in part because of mutations in regulators of Notch
signaling, including FBXW7 (although FBXW7 clearly controls
other cellular pathways beyond Notch) (Akhoondi et al., 2007;
Babaei-Jadidi et al., 2011; Camps et al., 2013; Miyaki et al.,
2009; Sancho et al., 2010; Zhu et al., 2013). In addition, Notch
activation has been linked to activation of Wnt signaling and
Hippo/YAP signaling in CRC cells, although the various levels
of crosstalk between these pathways are still not fully under-
stood (Camargo et al., 2007; Fre et al., 2009; Kim et al., 2012;
Kwon et al., 2011; Peignon et al., 2011; Rodilla et al., 2009;
Tschaharganeh et al., 2013). In particular, Jagged1, expressed
on tumor cells themselves or produced from endothelial cells,
is thought to be a key ligand for Notch activation in CRC cells
(Lu et al., 2013; Rodilla et al., 2009; Tschaharganeh et al.,
2013). Another Notch ligand, DLL4, plays a non-cell-autono-
mous role in CRC development, in large part by controlling the
development of blood vessels necessary for tumor growth
(Fischer et al., 2011; Ridgway et al., 2006). Expression of miR-
34a in CRC stem cells may help control Notch output and
generate a bimodal Notch response (Bu et al., 2013). Finally,
Notch signaling may play a crucial role not only in the early
stages of CRC development, by controlling the fate of stem cells
and cancer stem cells, but also in the later stages of tumor inva-
sion and metastasis (Sonoshita et al., 2011).
Pancreatic Cancer
The major and most lethal type of pancreatic cancer is pancre-
atic ductal adenocarcinoma (PDAC). An early study detected
evidence of Notch pathway activation in PDAC and showed
that Notch lies downstream of TGFß during ductal metaplasia,
an early stage of PDAC development (Miyamoto et al., 2003).
Mouse genetics studies have demonstrated that activation of
Notch signaling cooperates with oncogenic K-Ras to promote
both initiation and dysplastic progression from acinar cells by
inducing their rapid reprogramming to a duct-like phenotype
(De La O et al., 2008). Indeed, pharmacological inhibition of
Notch signaling slows the progression of the disease in mutant
mice and prevents the expansion of some humanPDAC cell lines
(Cook et al., 2012; Mizuma et al., 2012; Plentz et al., 2009),
possibly in part because of an inhibition of PDAC stem cells
(Bailey et al., 2014). Genetic inactivation of Notch2, but not
Notch1 (Avila et al., 2012; Mazur et al., 2010), inhibits PDAC
development initiated by oncogenic K-Ras. In fact, loss of
Notch1 function may even promote PDAC development,
although the basis of this observation remains unknown (Hanlon
et al., 2010).
Melanoma
The Notch pathway has been found to be active in melanoma
(Asnaghi et al., 2012). NOTCH1 appears to promote disease
progression (Rangarajan et al., 2001; Zhang et al., 2012) and
growth of melanocytes under hypoxic conditions (Bedogni
et al., 2008). There are no documented gain-of-function muta-
tions that affect the pathway in this disease (Hodis et al.,
2012), suggesting that the pathway might be affected through
transcriptional and epigenetic control, possibly via theCancer Cell 25, March 17, 2014 ª2014 Elsevier Inc. 325
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which acts as a repressor of the Notch pathway (Thurber et al.,
2011). Whatever the mechanism of activation, recent preclinical
studies have reported that g-secretase inhibitors (GSIs) can
reduce the tumor-initiating potential, and suggested that
combining GSIs with chemotherapy could be a useful new ther-
apeutic approach for melanoma (Huynh et al., 2011).
In conclusion, Notch signaling plays distinct roles in different
types of tumors, both solid and liquid (hematopoietic). This
review is by no means exhaustive, but provides a detailed
overview of Notch signaling in cancer. Most of the studies cited
here are recent, emphasizing the increasing interest in the role of
Notch signaling in cancer during the last decade. Mechanisti-
cally, more work is required to pinpoint specific molecular
pathways and gene targets in each tumor type, but emerging
technologies and, most notably, DNA and RNA next-genera-
tion sequencing-based approaches will continue to help us
further dissect the role of this pathway in tumor initiation and
progression.
A Perspective on Two Decades of Notch-Centered
Cancer Research: Remaining Intriguing Questions
This brief overview of some of the most common and/or lethal
human cancers, both hematopoietic and solid, highlight several
key aspects of the role of Notch signaling in cancer development
that hold true for other tumors in which Notch signaling is also
altered, including myeloma, prostate, ovarian, skin, and brain
cancers. Obviously, there are several outstanding questions
that have to be addressed to not only help us better understand
pathway function in cancer but also enable more efficient thera-
peutic targeting (see below). An initial question is whether Notch
pathway mutations are tumor initiating or tumor propagating.
Most likely, both types of mutations can be described depending
on the tumor type. We discussed an intriguing example in
myeloid neoplasms where Notch signaling loss of activity seems
to expand the frequency of leukemia-initiating cells, but requires
secondary mutational events to lead to full-blown disease (Klina-
kis et al., 2011; Lobry et al., 2013). A similar scenario might play
out in B-ALL, as it was shown that Notch activity directs lympho-
cyte progenitors exclusively to the T cell lineage, at the expense
of B cell differentiation (Pui et al., 1999; Radtke et al., 1999). On
the other hand, it is intriguing to ask whether NOTCH1-activating
mutations in T-ALL occur to simply define lineage, by locking
cells in a specific differentiation status (T cell in this case), or
to truly transform the cells. Further studies that allow genetic
sequencing of both leukemia and normal stem cell/progenitor
populations, preferably at the single-cell level, might be able to
address such questions.
One particularly interesting aspect of Notch signaling in cancer
progression that has been emerging in the last few years is its
potential impact on metastasis, which may be linked to the role
of Notch in cancer stem cells (see Giancotti, 2013, for a recent
discussion). Early studies identified JAG1 expression as a
marker of metastatic prostate cancer (Santagata et al., 2004)
and found a role for Notch in controlling the epithelial-mesen-
chymal transition (EMT) (Timmerman et al., 2004). Indeed,
JAG1 expression on tumor cells may help promote the spread
of breast cancer cells to the bone microenvironment by acti-
vating Notch signaling in bone cells (Sethi et al., 2011). Activation326 Cancer Cell 25, March 17, 2014 ª2014 Elsevier Inc.of Notch during EMT andmetastasis may be under the control of
the miR-200 microRNA (Brabletz et al., 2011; Yang et al., 2011).
This prometastatic function of Notch signaling may be promoted
by its crosstalk with the machinery that responds to hypoxic
environments (Sahlgren et al., 2008; Yeung et al., 2011). Further-
more, an increasing number of studies are connecting Notch
signaling to molecules and pathways involved in tumor invasion
and metastatic growth, including Tenascin C (Oskarsson et al.,
2011) and regulators of polarity (McCaffrey et al., 2012) in breast
cancer.
As discussed above, multiple studies have shown Notch
signaling in tumor cells to be involved in various aspects of
angiogenesis, especially via the DLL4 and JAG1 ligands (Bene-
dito et al., 2009; Li and Harris, 2005; Phng and Gerhardt, 2009;
Zeng et al., 2005). In particular, the Notch ligand DLL4 is up-
regulated in the angiogenic vasculature in response to vascular
endothelial growth factor (VEGF), and blockade of DLL4 was
shown to lead to markedly increased nonproductive tumor
vascularity, which inhibits tumor growth (Noguera-Troise et al.,
2006; Ridgway et al., 2006). Although these observations
seemed promising clinically (Hoey et al., 2009), long-term
blockade of DLL4 was shown to lead to the development of
vascular neoplasms (Yan et al., 2010), potentially limiting the
therapeutic potential of DLL4-blocking strategies. Thus, activa-
tion of Notch signaling may contribute to tumor spread via
multiple mechanisms, such as maintaining the self-renewal of
cancer stem cells, contributing directly to the cellular processes
involved in tumor invasion (e.g., EMT and response to hypoxia)
(Wang et al., 2011c), controlling neovascularization, and playing
a key role in the metastatic niche. Such issues could be more
important in solid tumors than in leukemia; however, it is
intriguing to define Notch-ligand-expressing niches in different
types of hematopoietic tumors, and to test whether ligand
expression is important for leukemia cell homing to different
tissues and response to drug treatments. For example, targeting
the expression or function of a specific ligand could affect
NOTCH1-expressing T-ALL homing and metastasis. As most
cancer patients die from metastatic disease, it will be important
in the near future to continue to investigate the molecular and
cellular bases of tumor spread in connection with Notch
signaling.
Therapeutic Targeting of the Notch Pathway in Tumors
Because proteolytic cleavage of NOTCH receptors by the prese-
nilin/g-secretase complex is a prerequisite for the activation of
signaling (in the absence of downstream activating mutations),
small-molecule GSIs efficiently block NOTCH1 activity in
T-ALL cells. Thus, the use of GSIs to inhibit NOTCH signaling
has been proposed as a molecular targeted therapy for treat-
ment of this disease (Aster and Blacklow, 2012; Palomero and
Ferrando, 2009). However, animal studies have shown that
systemic inhibition of NOTCH signaling results in ‘‘on-target’’
gastrointestinal toxicity because of the accumulation of secre-
tory goblet cells in the intestine due to alterations in the differen-
tiation of intestinal stem cells following Notch inactivation. Phase
1 clinical trials further confirmed these treatment side effects. As
a result, inhibition of the pathway using GSIs alone may not be
the most viable therapeutic choice in the future. An alternative
to single GSI treatment would be a combinatorial use of
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the GSI-induced gut toxicity by inducing the expression of Cyclin
D2, thereby protecting the animals from developing intestinal
goblet cell metaplasia (Real et al., 2009).
However, targeting of Notch signaling is not restricted to the
use of GSIs. a-Secretase inhibitors (ASIs) against the ADAM10/
17 metalloproteases that mediate receptor S2 cleavage are
available (Zhou et al., 2006) and are currently being tested
(Purow, 2012). Furthermore, using phage display technology,
pharmaceutical companies have generated highly specialized
antibodies against NOTCH1 and NOTCH2 that act mainly by
stabilizing the negative regulatory region of the receptors and
protecting against proteolytic cleavage, thus inhibiting the pro-
duction of ICN1/2 (Wu et al., 2010). These antibodies lead to
lower levels of gastrointestinal toxicity and other side effects
resulting from the pan-Notch pathway inhibition achieved by
GSIs. Selective blocking of NOTCH1 inhibits tumor growth in
preclinical models through at least two mechanisms: inhibition
of cancer cell growth and deregulation of angiogenesis. Soluble
extracellular fractions of Notch receptors and ligands can also
act as decoys and inhibit the pathway in a dominant-negative
manner. In one study, a Notch1 decoy decreased tumor cell
viability in xenograft models (Funahashi et al., 2008). However,
under different conditions, a DLL1 decoywas found to play either
an activating or an inhibitory role (Hicks et al., 2002). Thus, a bet-
ter understanding of the dynamics by which decoys work is
needed before they can be considered as a viable therapeutic
strategy.
Other types of experimental inhibitors entail synthetic peptides
that mimic MAML1 but lack its active domains. Although these
peptides are widely used for basic research purposes, their
use for therapeutic purposes is still limited. Moellering et al.
(2009) generated a synthetic, cell-permeable, a-helical peptide
(SAHM1) that blocks MAML1 recruitment and NOTCH-mediated
transcription as it binds with high affinity to the interface on the
NOTCH-CSL transactivation complex. Treatment of human
T-ALL cell lines and a mouse model of NOTCH1-driven T-ALL
with SAHM1 resulted in strong NOTCH-specific inhibition of
cell proliferation and leukemia progression (Moellering et al.,
2009).
Another intriguing idea for the treatment of tumors that are
induced by NOTCH and depend on pathway activity is to not
target theNotch pathway itself, and instead focus on its signaling
targets. Several such efforts are currently under way. Briefly, in-
vestigators have demonstrated in vivo T-ALL remission by
targeting (1) the NOTCH1-induced IKK kinase complex, which
plays a pivotal role in controlling the NF-kB pathway, which in
turn is strongly related to NOTCH in leukemia (Figure 4; Dan
et al., 2008; Espinosa et al., 2010; Vilimas et al., 2007); (2) the
CyclinD:CDK4/6 kinase complex, which is hyperactivated in
this type of acute leukemia (Sawai et al., 2012); and (3) the
bromodomain-containing protein BRD4 (King et al., 2013).
BRD proteins can be transcriptional coactivators and share
common binding patterns with T-ALL oncogenes NOTCH1 and
MYC in promoters and enhancers of key genes for the induction
and progression of the disease. Filippakopoulos et al. (2010)
recently modified a thienodiazepine molecule so that it inhibits
binding of BRD to the acetylated residues of histone H4. We
were able to show that such drugs can target both NOTCH1-and MYC-regulated transcription in T-ALL, leading to complete
disease remission in vivo (King et al., 2013). Such ‘‘epigeneti-
cally’’-targeted therapies might be particularly attractive consid-
ering the ability of Notch to alter locus accessibility and initiate
transcription. We recently connected NOTCH1 binding to loss
of H3K27me3 on target promoters, and demonstrated an antag-
onism between NOTCH1 binding and Polycomb complex 2
(PRC2) recruitment and activity (Ntziachristos et al., 2012).
Based on these findings, H3K27me3 demethylation inhibitors
might be an attractive therapy option in NOTCH1-induced
T-ALL (or CLL). Finally, recent evidence suggests that it may
be possible to inhibit Notch signaling by interfering with its traf-
ficking in cancer cell secretory pathways (Ilagan and Kopan,
2013; Kra¨mer et al., 2013).
Although a number of ‘‘anti-Notch’’ strategies are emerging, it
may be as important to specifically activate Notch in tumors
where activation of the Notch pathway is tumor suppressive.
As discussed above for AML, in cases where tumor cells express
a Notch receptor (NOTCH2) but do not show signs of pathway
activation, providing a ligand for these receptors or treating
them with activating antibodies may be sufficient to activate
the pathway in certain contexts and inhibit tumor growth.
Furthermore, in cases where Notch receptors are not expressed
(e.g., they are transcriptionally silenced), or some of their key
target genes are silenced, approaches to derepress the expres-
sion of these genes may be useful to slow cancer growth (Stock-
hausen et al., 2005).
Future Directions in the Understanding and Treatment
of Notch-Induced Tumors
The NOTCH pathway has been the intense focus of cancer
researchers for the last two decades. Unfortunately, there are
still no FDA-approved, Notch-targeted therapies. Retrospec-
tively, this is not surprising, as we now know that the pathway
plays key roles in several tissues, including adult differentiating
and regenerating tissues, which explains the potential side
effects of general inhibitors of the Notch pathway, such as
GSIs. The critical question is whether one can successfully target
the Notch pathway to significantly inhibit cancer growth. Another
major conundrum comes from the notion that Notch may play
distinct roles during several stages of the tumorigenic process,
an idea that has not been thoroughly examined. It is likely that in-
hibition of Notch signaling in tumors initiated by Notch-activating
mutations will have a therapeutic effect, as tumors are often
addicted to early initiating events. However, tumors in which
alterations in Notch pathway members occur late during tumor
evolution may rapidly invent ways to get around the targeting
of Notch.
We suggest that specificity should be the key for future
attempts to target NOTCH activity in cancer cells. One must
have a complete map of both Notch receptor and ligand expres-
sion in different cancers and their microenvironments to be
able to use antibodies or other small molecules that specifically
inhibit only the relevant molecules. Targeted (NOTCH-focused)
sequencing of tumors is also important to obtain a clear idea
of the type of mutation and its potential impact on pathway activ-
ity. Importantly, a large number of tumors that contain Notch-
activating mutations, such as the ICN1 translocation, cannot
be treated with GSIs. In contrast, receptor-specific antibodyCancer Cell 25, March 17, 2014 ª2014 Elsevier Inc. 327
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Notch signaling has a tumor-suppressive function. Myeloid neo-
plasms are a cancer subtype that could benefit from targeted
pathway activation, as we have shown that in such tumors the
pathway is inactive but the NOTCH2 receptor is expressed on
the surface of the cells and can be activated by ligand binding,
leading to cell death. Strategies to activate NOTCH in some
cancers are worth testing, first in preclinical models and hope-
fully in the near future in patients. Moreover, both Notch agonists
and antagonists could also be used in combination with current
treatments, including chemotherapy and more recent targeted-
therapies. In an intriguing example of such treatments, anti-
DLL4 antibodies were combined with either chemotherapy or
Avastin or VEGF traps to target tumor angiogenesis (Lobov
et al., 2011; Noguera-Troise et al., 2006). Another example is
the combination of NOTCH receptor inhibition (using GSIs or an-
tibodies) and glucocorticoids for the treatment of T-ALL (Real
et al., 2009).
Aswith other signaling pathways involved in cancer, identifica-
tion and targeting of NOTCH-interacting partners and targets
could be pivotal for the development of antitumor therapy proto-
cols. Some attempts have been made to identify such genes/
proteins using whole-proteome (mass spectrometry) (Yatim
et al., 2012) and genome/transcriptome (RNA-seq, gene array,
and ChIP-seq for NOTCH1 and HES1) (Ntziachristos et al.,
2012; Wang et al., 2011a) approaches. These studies suggest
that, apart from a small fraction of ‘‘universal’’ targets, including
members of the HES and HEY families, Notch pathway activity
controls the expression of a large number of tissue- and cell-
type-specific gene targets. Indeed, we have shown that
NOTCH2-HES1 signaling can regulate the expression of CEBPA
and PU1, two key regulators of myeloid differentiation, but these
genes are not affected by NOTCH pathway regulation in T-ALL.
Thus, the ability to target the function of tissue-specific Notch
pathway targets could offer more targeted therapies with fewer
side effects. In a similar fashion, it will be intriguing to define
the biochemical composition of the nuclear Notch complex in
different tissues to see whether there is a specificity that can
guide small-molecule-inhibition efforts.
Overall, it is fair to say that it took the scientific community
almost a century to reach the point where the basic molecular
tenets of NOTCH signaling are well understood. Similarly,
although we have known for the last two decades that Notch
signaling is involved in cancer, only recently have we developed
the means (e.g., small molecules and antibodies) to effectively
target pathway activation in this disease. There is still a sig-
nificant need for further research efforts to better define the
pathway and to propose drugs or drug combinations that can
affect Notch signaling specifically in cancer, avoiding harmful
side effects and improving both survival and quality of life for
patients with Notch-induced tumors.ACKNOWLEDGMENTS
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